104 Chapter 5 Group Hazard ratio (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 1.28 (1.14 to 1.44) Low dose tocilizumab 1.18 (1.03 to 1.34) Sarilumab 400mg 1.25 (1.11 to 1.39) Table 3: Multivariable Cox proportional hazards regression analysis with 60-day mortality as endpoint, correcting for age, sex, immunocompromised status and CCI, with imputed data Number needed to treat The unadjusted survival probability for the 8 mg/kg group at day 60 was 0.75. Combined with the hazard ratios from Table 5, the NNT was calculated (for calculations, see supplementary file). When comparing 8 mg/kg to the fixed dose tocilizumab group, the NNT was 24, meaning that treating 24 patients with an 8 mg/kg dosing regimen instead of the fixed dose group would prevent one death at day 60. I.e., when treating 1000 patients with the 8 mg/kg instead of a fixed dose, an additional 42 patients would be saved. When comparing 8 mg/kg to low dose tocilizumab, the NNT was 39, and 20 when comparing the 8 mg/kg group to the sarilumab group. Combined outcome We compared progression to the combined outcome of ICU admission or mortality between the different treatment groups. After correcting for confounders, the hazards for reaching the combined outcome were significantly higher for patients who received fixed dose tocilizumab, low dose tocilizumab or sarilumab compared with tocilizumab in an 8 mg/kg dosing regimen (Table 4). Group Hazard ratio (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 1.24 (1.09 to 1.42) Low dose tocilizumab 1.41 (1.22 to 1.63) Sarilumab 400mg 1.43 (1.26 to 1.63) Table 4: Cox proportional hazard analysis with admission to the ICU or mortality as the outcome variable, correcting for age, sex, immunocompromised status and CCI. Length of hospital stay The total hospital stay was shorter in low dose tocilizumab and sarilumab than the 8 mg/kg group, after correction for confounding (Supplementary Table 5). This effect
RkJQdWJsaXNoZXIy MTk4NDMw